卡那奴单抗作为完全切除的非小细胞肺癌患者辅助治疗:CANOPY-A双盲随机临床试验结果
CANOPY-A是一项III期随机双盲多中心研究,评估卡那奴单抗对比安慰剂用于已接受辅助顺铂化疗的完全切除II-IIIA或IIIB期非小细胞肺癌患者。共1382例患者随机接受卡那奴单抗200 mg(n=693)或安慰剂(n=689)每3周一次共18周期。研究未达到主要终点,中位无病生存期卡那奴单抗组35.0个月 vs 安慰剂组29.7个月(HR 0.94,95%CI 0.78-1.14,单侧P=0.258)。
要点
- CANOPY-A研究未达到主要终点,卡那奴单抗组与安慰剂组中位DFS无显著差异。
- 卡那奴单抗组与安慰剂组≥3级不良事件发生率分别为20.8%和19.6%,因不良事件停药率分别为4.3%和4.1%。
- 卡那奴单抗组C反应蛋白和IL-6水平较安慰剂组下降,但与临床结局差异无相关性。
核心结论
- CANOPY-A研究未显示在手术和辅助顺铂化疗后加用卡那奴单抗可改善切除的II-III期非小细胞肺癌患者的无病生存期。
- 卡那奴单抗未发现新的安全性信号。
研究设计与样本
- CANOPY-A(ClinicalTrials.gov标识符:NCT03447769)是一项III期随机双盲多中心研究,比较卡那奴单抗与安慰剂用于成人完全切除的II-IIIA或IIIB期(T>5 cm,N2阳性II-IIIB;美国癌症联合委员会/国际抗癌联盟第8版)非小细胞肺癌患者,这些患者已接受辅助顺铂为基础的化疗。
- 主要终点为无病生存期,关键次要终点为总生存期。
- 共1382例患者随机分配至卡那奴单抗200 mg组(n=693)或安慰剂组(n=689),每3周一次,共18个周期。
主要发现
- 卡那奴单抗组和安慰剂组≥3级不良事件发生率分别为20.8%和19.6%;因不良事件导致停药的患者比例分别为4.3%和4.1%。
- 研究未达到主要终点:中位无病生存期卡那奴单抗组为35.0个月,安慰剂组为29.7个月(风险比0.94;95%CI 0.78至1.14;单侧P=0.258)。
- 无病生存期亚组分析未显示两组间有任何有意义的差异。
- 如预期,由于卡那奴单抗驱动的IL-1β通路抑制,卡那奴单抗组较安慰剂组C反应蛋白和IL-6水平下降,但与临床结局差异无相关性。
- 由于无病生存期未达统计学显著,总生存期未进行正式检验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Effective treatments for resectable non-small-cell lung cancer (NSCLC) are limited and relapse rates are high. The interleukin (IL)-1β pathway has been linked with tumor development and progression, including in the Canakinumab Anti-Inflammatory Thrombosis Outcomes cardiovascular study in which IL-1β pathway inhibition with canakinumab reduced lung cancer incidence and mortality in an exploratory analysis. METHODS: CANOPY-A (ClinicalTrials.gov identifier: NCT03447769) is a phase III, randomized, double-blind, multicenter study of canakinumab versus placebo for adult patients with stage II-IIIA or IIIB (T >5 cm, N2-positives II-IIIB; American Joint Committee on Cancer/Union for International Cancer Control version 8), completely resected NSCLC who had received adjuvant cisplatin-based chemotherapy. The primary end point was disease-free survival (DFS) and the key secondary end point was overall survival (OS). RESULTS: In total, 1,382 patients were randomized to 200 mg canakinumab (n = 693) or placebo (n = 689) once every 3 weeks for 18 cycles. Grade ≥3 adverse events (AEs) were reported in 20.8% and 19.6% of patients receiving canakinumab and placebo, respectively; AEs led to discontinuation in 4.3% and 4.1% of patients in these groups, respectively. This study did not meet its primary end point. Median DFS was 35.0 months (canakinumab arm) and 29.7 months (placebo arm; hazard ratio, 0.94; 95% CI, 0.78 to 1.14; one-sided P = .258). DFS subgroup analyses did not show any meaningful differences between arms. As expected, because of canakinumab-driven IL-1β pathway inhibition, C-reactive protein and IL-6 levels decreased in the canakinumab arm versus placebo arm, but had no correlation with differential clinical outcomes. OS was not formally tested as DFS was not statistically significant. CONCLUSION: CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC. No new safety signals were identified with canakinumab.
引用
- Garon EB, Lu S, Goto Y, et al. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. J Clin Oncol. 2023. PMID: 37788412. doi:10.1200/JCO.23.00910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。